Network Pharmacology and Molecular Docking-Based Approach Revealing the Potential Anticancer Compounds and Molecular Mechanisms of Paris polyphylla Against Colorectal Cancer.

Colorectal cancer (CRC) remains a major cause of cancer-related morbidity and mortality worldwide, highlighting the need for safer and more effective therapeutic agents. This study investigated the potential anticancer compounds and mechanisms of Paris polyphylla against CRC using an integrated approach combining network pharmacology, molecular docking, and in vitro validation. Bioactive compounds were screened from multiple databases, and their putative targets were intersected with CRC-related genes. Protein-protein interaction and enrichment analyses were performed to identify key targets and pathways, followed by the docking of selected compounds with major hub proteins. The cytotoxic and molecular effects of P. polyphylla rhizome extract (PPRE) were then evaluated in SW480 and HCT116 cells. A total of 74 compounds were identified, of which 12 were retained for target prediction, yielding 180 overlapping genes between P. polyphylla targets and CRC-associated genes. Network analysis highlighted STAT3, EGFR, SRC, IL-6, and AKT1 as key hub targets, with enrichment in cancer-related, EGFR resistance, and PI3K-Akt pathways. Docking showed favorable binding affinities, particularly between prosapogenin A and AKT1. Experimentally, PPRE reduced CRC cell viability and downregulated STAT3, EGFR, SRC, IL-6, and AKT1 expression. These findings suggest that P. polyphylla exerts anticancer effects through the coordinated modulation of multiple oncogenic pathways in CRC.